|
- B-Cell Precursor ALL Treatment | BLINCYTO® (blinatumomab)
Learn about BLINCYTO® (blinatumomab), a treatment for B-cell precursor acute lymphoblastic leukemia (ALL) in both children and adults See Safety Information, including Boxed Warnings
- Dosing Information | BLINCYTO® (blinatumomab)
View dosing info for BLINCYTO®, an intravenous (IV) infusion, including a dosing schedule what to expect during treatment See Safety Info, including Boxed Warnings
- Patient Resources | BLINCYTO® (blinatumomab)
Do not drive, operate heavy machinery, or do other dangerous activities while you are receiving BLINCYTO® because BLINCYTO® can cause neurological symptoms such as dizziness, seizures, and confusion
- Adults with Acute Lymphoblastic Leukemia - BLINCYTO
See what makes BLINCYTO® immunotherapy for acute lymphoblastic leukemia (ALL) different from other ALL treatments for adults See Safety Info, including Boxed Warnings
- Relapsed or Refractory B-Cell ALL Treatment - BLINCYTO
Review information about how BLINCYTO® (blinatumomab) treats relapsed or refractory acute lymphoblastic leukemia (ALL) See Safety Information, including Boxed Warnings
- Adults with Acute Lymphoblastic Leukemia - BLINCYTO
See what makes BLINCYTO® treatment for adults with acute lymphoblastic leukemia (ALL) different from other adult ALL treatments, including side effects See Safety Info, including Boxed Warnings
- Consolidation B-Cell Precursor ALL Treatment - BLINCYTO
Learn about Ph (-) B-cell acute lymphoblastic leukemia (ALL) immunotherapy treatment with BLINCYTO® See Safety Info, including Boxed Warnings
- Children with Acute Lymphoblastic Leukemia - BLINCYTO
What is BLINCYTO ®? BLINCYTO ® is an immunotherapy used to treat BCP-ALL in adults and children one month or older 1 It is different from chemotherapy because it engages your immune system to find and kill cancer cells 1,2
|
|
|